0000000001190367

AUTHOR

E Bonora

showing 6 related works from this author

Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular …

2012

Abstract Background and aims Metformin is the first-line therapy in type 2 diabetes. In patients inadequately controlled with metformin, the addition of a sulfonylurea or pioglitazone are equally plausible options to improve glycemic control. However, these drugs have profound differences in their mechanism of action, side effects, and impact on cardiovascular risk factors. A formal comparison of these two therapies in terms of cardiovascular morbidity and mortality is lacking. The TOSCA.IT study was designed to explore the effects of adding pioglitazone or a sulfonylurea on cardiovascular events in type 2 diabetic patients inadequately controlled with metformin. Methods Multicentre, random…

Blood GlucoseMaleBIO/12 - BIOCHIMICA CLINICA E BIOLOGIA MOLECOLARE CLINICAEndocrinology Diabetes and Metabolismpioglitazone sulfonylurea type 2 diabetes metformin cardiovascular eventsMedicine (miscellaneous)Type 2 diabetesSettore MED/13 - EndocrinologiaBody Mass Indexlaw.inventionRandomized controlled trialRisk FactorslawSurveys and QuestionnairesCardiovascular DiseasepioglitazonepiogllitazoneStrokeDiabetes Therapy PioglitazoneNutrition and DieteticsDiabetesThiazolidinedionecardiovascular events; pioglitazone; Type 2 Diabetes Mellitus; sulphonylureasType 2 diabetesMiddle AgedMetforminSulfonylurea CompoundTreatment OutcomeTolerabilitysulphonylureasCardiovascular DiseasesDrug Therapy CombinationFemaletype 2 diabetesCardiology and Cardiovascular MedicineHumanmedicine.drugmedicine.medical_specialtyEndpoint Determinationsulfonylureacardiovascualr eventSudden deathFollow-Up Studiecardiovascular eventsInternal medicineDiabetes mellitusmedicineHumansHypoglycemic Agentssulfonylureasinterventio trialtype 2 diabetes; cardiovascular events; pioglitazone; sulfonylureas; randomized controlled trialAgedHypoglycemic AgentQuestionnairebusiness.industryRisk Factormedicine.diseaseSurgeryType 2 Diabetes MellitusSulfonylurea CompoundsDiabetes Mellitus Type 2randomized controlled trialQuality of LifeThiazolidinedionesTherapybusinessmetforminPioglitazoneFollow-Up Studies
researchProduct

Higher Fluid Balance Increases the Risk of Death From Sepsis: Results From a Large International Audit

2017

Contains fulltext : 177598.pdf (Publisher’s version ) (Closed access) OBJECTIVES: Excessive fluid therapy in patients with sepsis may be associated with risks that outweigh any benefit. We investigated the possible influence of early fluid balance on outcome in a large international database of ICU patients with sepsis. DESIGN: Observational cohort study. SETTING: Seven hundred and thirty ICUs in 84 countries. PATIENTS: All adult patients admitted between May 8 and May 18, 2012, except admissions for routine postoperative surveillance. For this analysis, we included only the 1,808 patients with an admission diagnosis of sepsis. Patients were stratified according to quartiles of cumulative f…

InternationalityTime FactorsDatabases Factualmedicine.medical_treatmentlnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4]Settore MED/41 - AnestesiologiaCritical Care and Intensive Care Medicinelaw.invention0302 clinical medicinelawRisk Factors80 and over030212 general & internal medicineHospital Mortality610 Medicine & healthAged 80 and overMedical Auditfluid outputMiddle AgedWater-Electrolyte Balancefluid administrationIntensive care unitfluid administration; fluid output; outcome; septic shock; Adult; Aged; Aged 80 and over; Databases Factual; Hospital Mortality; Humans; Intensive Care Units; Internationality; Medical Audit; Middle Aged; Risk Factors; Sepsis; Time Factors; Fluid Therapy; Water-Electrolyte Balance; Critical Care and Intensive Care MedicineIntensive Care UnitsCohortoutcomeHumanCohort studyAdultmedicine.medical_specialtyTime FactorSepsiIntensive Care UnitObservational StudySepsis03 medical and health sciencesDatabasesSepsisHemofiltrationmedicineJournal ArticleHumansRisk factorIntensive care medicineFactualHetastarchAgedbusiness.industrySeptic shockRisk Factor030208 emergency & critical care medicinefluid administration fluid output outcome septic shockmedicine.diseaseseptic shockFluid Therapybusiness
researchProduct

Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes): A multicenter retrospective nationwide Italian study a…

2017

Background Randomized controlled trials (RCTs) in the field of diabetes have limitations inherent to the fact that design, setting, and patient characteristics may be poorly transferrable to clinical practice. Thus, evidence from studies using routinely accumulated clinical data are increasingly valued. Aims We herein describe rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes), a multicenter retrospective nationwide study conducted at 50 specialist outpatient clinics in Italy and promoted by the Italian Diabetes Society. Data synthesis The primary objective of the study is to describe the baseline clinical characteristics (particularly HbA1c) of pa…

randomized controlled trial; real-life; retrospective study; sodium glucose co-transporter-2 inhibitor; medicine (miscellaneous); endocrinology; diabetes and metabolism; nutrition and dietetics; cardiology and cardiovascular medicineBlood GlucoseTime FactorsGlucosideGlycated Hemoglobin ATime FactorMedicine (miscellaneous)Settore MED/13 - EndocrinologiaEndocrinologyGlucosidesSodium-Glucose Transporter 2Retrospective StudieDiabetes MellitusHumansHypoglycemic AgentsData MiningBenzhydryl CompoundsRandomized controlled trial; Real-life; Retrospective study; Sodium glucose co-transporter-2 inhibitor; Benzhydryl Compounds; Biomarkers; Blood Glucose; Data Mining; Diabetes Mellitus Type 2; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemic Agents; Italy; Research Design; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Crowdsourcing; Evidence-Based Medicine; Medicine (miscellaneous); Endocrinology Diabetes and Metabolism; Nutrition and Dietetics; Cardiology and Cardiovascular MedicineSodium-Glucose Transporter 2 InhibitorsRetrospective StudiesGlycated HemoglobinBenzhydryl CompoundNutrition and DieteticsEvidence-Based MedicineHypoglycemic AgentSodium-Glucose Transporter 2 InhibitorRandomized controlled trial; Real-life; Retrospective study; Sodium glucose co-transporter-2 inhibitor; Benzhydryl Compounds; Biomarkers; Blood Glucose; Data Mining; Diabetes Mellitus Type 2; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemic Agents; Italy; Research Design; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Crowdsourcing; Evidence-Based MedicineReal-lifeBiomarkerDiabetes and MetabolismRandomized controlled trial; Real-life; Retrospective study; Sodium glucose co-transporter-2 inhibitor; Benzhydryl Compounds; Biomarkers; Blood Glucose; Data Mining; Diabetes Mellitus Type 2; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemic Agents; Italy; Research Design; Retrospective Studies; Sodium-Glucose Transporter 2; Time Factors; Treatment Outcome; Crowdsourcing; Evidence-Based Medicine; Medicine (miscellaneous); Endocrinology Diabetes and Metabolism; Nutrition and Dietetics; Cardiology and Cardiovascular MedicineRetrospective studyTreatment OutcomeDiabetes Mellitus Type 2ItalyRandomized controlled trialResearch DesignSodium glucose co-transporter-2 inhibitorCrowdsourcingCardiology and Cardiovascular MedicineBiomarkersType 2Human
researchProduct

Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective …

2018

Introduction DPP-4 inhibitors (DPP4i) and sulfonylureas are popular second-line therapies for type 2 diabetes (T2D), but there is a paucity of real-world studies comparing their effectiveness in routine clinical practice. Methods This was a multicenter retrospective study on diabetes outpatient clinics comparing the effectiveness of DPP4i versus gliclazide extended release. The primary endpoint was change from baseline in HbA1c. Secondary endpoints were changes in fasting plasma glucose, body weight, and systolic blood pressure. Automated software extracted data from the same clinical electronic chart system at all centers. Propensity score matching (PSM) was used to generate comparable coh…

endocrine systemmedicine.medical_specialtyEpidemiologyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabetes030204 cardiovascular system & hematologyDatabase03 medical and health sciences0302 clinical medicineEndocrinologyDiabetes mellitusInternal medicinemedicineClinical endpointDatabase; Epidemiology; Pharmacotherapy; Internal Medicine; Endocrinology Diabetes and MetabolismInternal MedicineOutpatient clinicGliclazideOriginal ResearchGlycemicbusiness.industrynutritional and metabolic diseasesDatabase; Epidemiology; PharmacotherapyRetrospective cohort studymedicine.diseasePharmacotherapyMetforminDiabetes and Metabolismbusinessmedicine.drug
researchProduct

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately …

2017

Background The best treatment option for patients with type 2 diabetes in whom treatment with metformin alone fails to achieve adequate glycaemic control is debated. We aimed to compare the long-term effects of pioglitazone versus sulfonylureas, given in addition to metformin, on cardiovascular events in patients with type 2 diabetes. Methods TOSCA.IT was a multicentre, randomised, pragmatic clinical trial, in which patients aged 50–75 years with type 2 diabetes inadequately controlled with metformin monotherapy (2–3 g per day) were recruited from 57 diabetes clinics in Italy. Patients were randomly assigned (1:1), by permuted blocks randomisation (block size 10), stratified by site and…

MaleDiabetes and Metabolism ipoglycemic drugs cardiovascualr eventSettore MED/09 - Medicina Internaendocrine system diseasesIMPACTpioglitazone versus sulfonylureasEndocrinology Diabetes and MetabolismGLIMEPIRIDEDiabetes cardiovascular events metformin pioglitazone sulphonylureasType 2 diabetes030204 cardiovascular system & hematologyInternal Medicine; Endocrinology Diabetes and Metabolism; Endocrinologylaw.inventionSettore MED/13 - EndocrinologiaGlibenclamide0302 clinical medicineRandomized controlled triallawGLYCEMIC CONTROLGliclazideInternal medicinediabetes and metabolismRISKeducation.field_of_studydiabetesIncidenceInternal medicine; endocrinology diabetes and metabolism; endocrinologyMiddle AgedINSULINMetforminMetforminTreatment OutcomeEditorialsulphonylureasCardiovascular DiseasesCombinationDrug Therapy CombinationFemaleType 2medicine.drugmedicine.medical_specialtyPopulation030209 endocrinology & metabolismAged; Cardiovascular Diseases; Diabetes Mellitus Type 2; Drug Therapy Combination; Female; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment OutcomeCardiovascular events03 medical and health sciencesendocrinologyGLUCOSE-LOWERING DRUGSDrug TherapyInternal medicineDiabetes MellitusmedicineHumansHypoglycemic AgentssulfonylureaseducationTOSCA.ITAgedPioglitazonebusiness.industryMORTALITYnutritional and metabolic diseasesInsulin resistancemedicine.diseaseSurgeryGlimepirideSulfonylurea CompoundsDiabetes Mellitus Type 2Diabetes Mellitus; Pioglitazone; Insulin resistanceThiazolidinedionesbusinessFOLLOW-UPPioglitazone
researchProduct

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

2017

Item does not contain fulltext BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent re…

MaleSTATIN THERAPYAnticholesteremic Agents/adverse effectsAntibodieVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Injections Subcutaneous/adverse effects030204 cardiovascular system & hematologyBococizumablaw.inventionPCSK90302 clinical medicineRandomized controlled triallawRisk FactorsGENETIC-VARIANTSCardiovascular DiseaseMonoclonalAnticholesteremic Agent030212 general & internal medicineMyocardial infarctionTreatment FailureHumanizedProprotein Convertase 9/antagonists & inhibitorsMedicine(all)Antibodies; Antibodies Monoclonal Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections Subcutaneous; Lipids; Male; Middle Aged; Proprotein Convertase 9; Risk Factors; Treatment Failure; Medicine (all)Anticholesteremic AgentsMedicine (all)PCSK9 InhibitorsAntibodies; antibodies monoclonal humanized; anticholesteremic agents; cardiovascular diseases; cholesterol LDL; double-blind method; female; follow-up studies; humans; hypercholesterolemia; injections subcutaneous; lipids; male; middle aged; proprotein convertase 9; risk factors; treatment failure; medicine (all)Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]General MedicineLipidMiddle AgedLipids3. Good healthLDL/bloodMulticenter StudyCholesterolTRIALSCholesterol LDL/bloodCardiovascular DiseasesAntibodies Monoclonal Humanized/adverse effectsanticholesteremic agentsRandomized Controlled Trialsubcutaneouslipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Cardiovascular Diseases/prevention & controlREDUCING LIPIDSHumanmedicine.medical_specialtyanimal structuresInjections SubcutaneousHypercholesterolemiaHypercholesterolemia/drug therapyPlaceboAntibodies Monoclonal HumanizedInjections SubcutaneouAntibodiesLDLInjectionsFollow-Up StudielipidsEVENTS03 medical and health sciencesantibodies monoclonal humanizedDouble-Blind MethodInternal medicinemedicineJournal ArticleHumansComparative StudyMETAANALYSISAlirocumabbusiness.industryUnstable anginaLipids/bloodPCSK9Risk FactorfungiAntibodies/bloodCholesterol LDLta3121medicine.diseaseSurgerycardiovascular diseasesEvolocumabREDUCTIONHumanized/adverse effectsSubcutaneous/adverse effectsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct